Leukeran

Chlorambucil, the active ingredient in Leukeran, is a alkylating agent presented as a tablet for oral use. It treats certain lymphoid malignancies such as chronic lymphocytic leukemia, Hodgkin's lymphoma and non‑Hodgkin's lymphoma in adult patients.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran (chlorambucil) is employed in the management of malignant disorders of the lymphoid system.

- Chronic lymphocytic leukemia: provides disease control and prolongs survival. - Hodgkin's lymphoma: induces remission in eligible patients. - Non‑Hodgkin's lymphoma: reduces tumor burden and improves clinical outcomes. - Other lymphoid malignancies: offers therapeutic benefit as part of combination regimens.

Adverse reactions may occur with chlorambucil therapy.

Common Side Effects: - Nausea and vomiting. - Loss of appetite. - Fatigue or generalized weakness. - Mild leukopenia or neutropenia. - Alopecia (hair loss). - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia. - Life‑threatening infections due to profound neutropenia. - Secondary malignancies such as acute leukemia. - Hepatic toxicity with elevated liver enzymes. - Pulmonary fibrosis or interstitial lung disease. - Severe hypersensitivity reactions including anaphylaxis.

Before initiating chlorambucil, several safety considerations are recommended.

- Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: obtain baseline and periodic liver enzyme tests. - Evaluate renal function: adjust therapy if significant impairment exists. - Avoid use during active severe infection: defer treatment until infection resolves. - Use effective contraception: potential teratogenic risk requires pregnancy prevention. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Chlorambucil may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents (e.g., other alkylators) may exacerbate bone marrow toxicity. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Anticoagulants: increased bleeding tendency.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Antacids or supplements containing aluminum/magnesium: could affect oral absorption. - CYP450 inhibitors or inducers: may alter chlorambucil plasma levels, requiring dose adjustment or monitoring.